AEs led to study discontinuation in 37 patients receiving dapagliflozin (9.1%) versus 24 receiving glipizide (5.9%), which
was mainly accounted for by an excess of patients who were withdrawn because of decreased calculated creatinine clearance with dapagliflozin (n = 13) versus glipizide (n = 6; Table 1).